#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Diabetes

We recommend klinickastudie

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

5. 12. 2023 Source: Diabetes

Modern antidiabetics – gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) – significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio- and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been…

srdce

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i,…
5. 12. 2023 Source: Diabetes
ledviny

Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type…
18. 10. 2023 Source: Diabetes

Articles on this topic
diabetik_mereni_cukru_glukoza_cukrovka_diabetes

Diabetic Nephropathy and COVID-19: Fatal Connection?

People with diabetes and diabetic kidney disease exhibit higher mortality and risk of severe…
26. 4. 2021 Source: Diabetes
diabeticka_noha_muz

Diabetic Foot Syndrome: An Unpleasant Scare for Diabetics and Their Attending Doctors

Diabetic foot syndrome is a very serious complication of diabetes mellitus (DM). It often…
8. 3. 2021 Source: Diabetes
PL_oko_starsi_zena_vrasky

Diabetic Retinopathy: A Blind Diabetic as Proof of Serious Neglect of Prevention

Diabetic retinopathy is the most common cause of blindness in working-age patients in…
1. 3. 2021 Source: Diabetes
z UL

DPP4 Inhibitors in Chronic Kidney Disease and Their Potential to Protect Against Diabetic Nephropathy

Preclinical and clinical observations suggest that dipeptidyl peptidase 4 (DPP4) inhibitors might...
14. 12. 2020 Source: Diabetes
PL_zena_lekar_konzultace

Patient with Diabetes: When to Follow Up and When to Refer to a Specialist?

It is most often the general practitioner (GP) who first diagnoses diabetes. Whether during…
6. 12. 2020 Source: Diabetes
predepsani_leku_recept

Gliflozins in the Treatment of Type 2 Diabetes According to Current Recommendations SVL

Gliflozins are a relatively new group of antidiabetics with a specific mechanism of action. In…
24. 11. 2020 Source: Diabetes
diabetes_cukrovka_medicína

Case Study with Voting: Intensification of Type 2 Diabetes Therapy in a Chronically Treated Patient. How to Proceed According to Current Recommendations?

We have prepared an interactive case study for you with a 70-year-old patient with decompensated...
12. 11. 2020 Source: Diabetes
kamaradky_seniorky_zeny_kavarna_volny_cas_radost

Desirable Side Effects of Antidiabetics

The days when diabetology was a field solely focused on normalizing blood sugar levels are…
6. 11. 2020 Source: Diabetes
leky_medikace_vyber_doporuceni_preskripce

Prescription Restrictions on Antidiabetics Authorized for Prescription by General Practitioners - Status as of October 2020

Diabetes mellitus (DM) has become an increasing problem worldwide in recent years. Long-term…
15. 10. 2020 Source: Diabetes
predepsani_leku_recept

10 Properties and Benefits of Gliptins: How They Work and When to Prescribe Them

General practitioners can now prescribe oral antidiabetics from the group of gliptins to…
28. 8. 2020 Source: Diabetes

1 2 3 4 5
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#